VRDN Relative Valuation
VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRDN is overvalued; if below, it's undervalued.
Historical Valuation
Viridian Therapeutics Inc (VRDN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.71. The fair price of Viridian Therapeutics Inc (VRDN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：31.24
Fair
-7.98
PE
1Y
3Y
5Y
Trailing
Forward
-7.81
EV/EBITDA
Viridian Therapeutics Inc. (VRDN) has a current EV/EBITDA of -7.81. The 5-year average EV/EBITDA is -3.68. The thresholds are as follows: Strongly Undervalued below -7.51, Undervalued between -7.51 and -5.59, Fairly Valued between -1.77 and -5.59, Overvalued between -1.77 and 0.15, and Strongly Overvalued above 0.15. The current Forward EV/EBITDA of -7.81 falls within the Strongly Undervalued range.
-6.45
EV/EBIT
Viridian Therapeutics Inc. (VRDN) has a current EV/EBIT of -6.45. The 5-year average EV/EBIT is -3.18. The thresholds are as follows: Strongly Undervalued below -5.73, Undervalued between -5.73 and -4.46, Fairly Valued between -1.91 and -4.46, Overvalued between -1.91 and -0.63, and Strongly Overvalued above -0.63. The current Forward EV/EBIT of -6.45 falls within the Strongly Undervalued range.
67.02
PS
Viridian Therapeutics Inc. (VRDN) has a current PS of 67.02. The 5-year average PS is 2449.17. The thresholds are as follows: Strongly Undervalued below -2717.20, Undervalued between -2717.20 and -134.02, Fairly Valued between 5032.35 and -134.02, Overvalued between 5032.35 and 7615.53, and Strongly Overvalued above 7615.53. The current Forward PS of 67.02 falls within the Historic Trend Line -Fairly Valued range.
-8.57
P/OCF
Viridian Therapeutics Inc. (VRDN) has a current P/OCF of -8.57. The 5-year average P/OCF is -4.22. The thresholds are as follows: Strongly Undervalued below -8.79, Undervalued between -8.79 and -6.50, Fairly Valued between -1.93 and -6.50, Overvalued between -1.93 and 0.36, and Strongly Overvalued above 0.36. The current Forward P/OCF of -8.57 falls within the Undervalued range.
-8.82
P/FCF
Viridian Therapeutics Inc. (VRDN) has a current P/FCF of -8.82. The 5-year average P/FCF is -4.68. The thresholds are as follows: Strongly Undervalued below -8.41, Undervalued between -8.41 and -6.55, Fairly Valued between -2.82 and -6.55, Overvalued between -2.82 and -0.95, and Strongly Overvalued above -0.95. The current Forward P/FCF of -8.82 falls within the Strongly Undervalued range.
Viridian Therapeutics Inc (VRDN) has a current Price-to-Book (P/B) ratio of 8.19. Compared to its 3-year average P/B ratio of 4.09 , the current P/B ratio is approximately 100.38% higher. Relative to its 5-year average P/B ratio of 4.17, the current P/B ratio is about 96.32% higher. Viridian Therapeutics Inc (VRDN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -16.60%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -18.44% , the current FCF yield is about -100.00% lower.
8.50
P/B
Median3y
4.09
Median5y
4.17
-10.92
FCF Yield
Median3y
-16.60
Median5y
-18.44
Competitors Valuation Multiple
The average P/S ratio for VRDN's competitors is , providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 81958.14%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VRDN increased by 69.33% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 86.00K to 70.57M.
The secondary factor is the Margin Expansion, contributed -99.95%to the performance.
Overall, the performance of VRDN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Viridian Therapeutics Inc (VRDN) currently overvalued or undervalued?
What is Viridian Therapeutics Inc (VRDN) fair value?
How does VRDN's valuation metrics compare to the industry average?
What is the current P/B ratio for Viridian Therapeutics Inc (VRDN) as of Dec 05 2025?
What is the current FCF Yield for Viridian Therapeutics Inc (VRDN) as of Dec 05 2025?
What is the current Forward P/E ratio for Viridian Therapeutics Inc (VRDN) as of Dec 05 2025?